OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 15:44:33 2024-05-10 EDT | ||
| 54.93 EUR | -1.91% |
|
| Current month | -3.90% | ||
| 1 month | -0.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 54.93 | -1.91% | 0 |
| 24-05-09 | 56 | -0.80% | 0 |
| 24-05-08 | 56.45 | -0.28% | 0 |
| 24-05-07 | 56.61 | +2.18% | 0 |
| 24-05-06 | 55.4 | +4.98% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 03:44 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SD9F17 |
| ISIN | DE000SD9F170 |
| Date issued | 2020-12-04 |
| Strike | 169.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 57.99 € |
|---|---|
| Lowest since issue | 0.69 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
- Stock Market
- Certificates
- Certificat